Each year in the UK, 30,000 children under the age of five are hospitalised with RSV and it causes around 30 infant deaths.

Respiratory syncytial virus (RSV) is a well-known cause of infections in children, but it's understudied in older individuals ...

Respiratory syncytial virus (RSV) poses a significant, often overlooked, risk for serious cardiovascular complications in ...

Respiratory syncytial virus (RSV) is a well-known cause of infections in children, but it's understudied in older individuals. In a retrospective study published in the Journal of the American ...

Winter is here, and with it come higher rates of respiratory illnesses. If you've been struck down recently with a sore ...

The CDC recently updated RSV vaccine recommendations to include certain adults aged 50 and up. When is the best time to get ...

A new respiratory syncytial virus vaccine to protect infants from severe illness is available in South Africa’s private sector, but not yet in public clinics. The country’s advisory group on ...

Sanofi acquires Vicebio for $1.15 billion, adding a next-gen RSV-hMPV vaccine and ‘Molecular Clamp' tech to strengthen its respiratory vaccine pipeline.

The largest US real-world study of BEYFORTUS (nirsevimab-alip) 50mg and 100mg Injection successfully met both of its co-primary endpoints, demonstrating that BEYFORTUS provides protection for babies ...

Sanofi has signed an agreement to acquire Vicebio’s share capital for $1.15bn upfront, to expand its vaccine development capabilities.

Respiratory syncytial virus (RSV) is a well-known cause of infections in children, but it's understudied in older individuals. In a retrospective ...

Babies born very prematurely will be offered protection against respiratory syncytial virus (RSV) with a long-acting antibody ...